PI3K inhibitors are finally coming of age
Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
Numerous agents targeting various phosphatidylinositol 3-kinase (PI3K) pathway
components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials …
components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials …
The present and future of PI3K inhibitors for cancer therapy
Abstract Phosphoinositide 3-kinase (PI3K) signaling regulates cellular proliferation, survival
and metabolism, and its aberrant activation is one of the most frequent oncogenic events …
and metabolism, and its aberrant activation is one of the most frequent oncogenic events …
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the
standard first-line treatment for most patients with hormone receptor (HR) positive, human …
standard first-line treatment for most patients with hormone receptor (HR) positive, human …
Self‐stabilized supramolecular assemblies constructed from PEGylated dendritic peptide conjugate for augmenting tumor retention and therapy
X Zheng, D Pan, X Chen, L Wu, M Chen… - Advanced …, 2021 - Wiley Online Library
Supramolecular self‐assemblies of dendritic peptides with well‐organized nanostructures
have great potential as multifunctional biomaterials, yet the complex self‐assembly …
have great potential as multifunctional biomaterials, yet the complex self‐assembly …
Dysregulated amino acid sensing drives colorectal cancer growth and metabolic reprogramming leading to chemoresistance
Background & Aims Colorectal cancer (CRC) is a devastating disease that is highly
modulated by dietary nutrients. Mechanistic target of rapamycin complex 1 (mTORC1) …
modulated by dietary nutrients. Mechanistic target of rapamycin complex 1 (mTORC1) …
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 …
The PI3K pathway is commonly activated in breast cancer, with PI3K-AKT pathway inhibitors
used clinically. However, mechanisms that limit or enhance the therapeutic effects of PI3K …
used clinically. However, mechanisms that limit or enhance the therapeutic effects of PI3K …
Phosphoinositide 3-kinase (PI3K) inhibitors and breast cancer: an overview of current achievements
Simple Summary Breast cancer remains the fourth-leading cause of death worldwide, and
therapeutic improvement is warranted. The phosphatidylinositol 3-kinase (PI3K) pathway is …
therapeutic improvement is warranted. The phosphatidylinositol 3-kinase (PI3K) pathway is …
Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA‐mutant cervical carcinoma via the PI3K/AKT pathway
Y Wei, S Lin, W Zhi, T Chu, B Liu, T Peng… - Journal of Medical …, 2023 - Wiley Online Library
Cervical carcinoma is a serious type of gynecological cancer that can affect women of all
ages. Cervical carcinoma presents challenges for precision medicine, as not all tumors have …
ages. Cervical carcinoma presents challenges for precision medicine, as not all tumors have …
The role of TSC2 in breast cancer: a literature review
QY Zhu, ZM He, WM Cao, B Li - Frontiers in Oncology, 2023 - frontiersin.org
TSC2 is a tumor suppressor gene as well as a disease-causing gene for autosomal
dominant disorder tuberous sclerosis complex (TSC). Research has found that some tumor …
dominant disorder tuberous sclerosis complex (TSC). Research has found that some tumor …